Press Releases InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules June 27, 2025 Read More » InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 25, 2025 Read More » InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study June 24, 2025 Read More » InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA June 13, 2025 Read More » InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update May 12, 2025 Read More » InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update February 12, 2025 Read More » InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration February 3, 2025 Read More » InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds January 22, 2025 Read More » InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study January 21, 2025 Read More » InMed Announces Results of 2024 Annual General Meeting December 18, 2024 Read More » InMed Enters Into Standby Equity Purchase Agreement December 17, 2024 Read More » InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System November 19, 2024 Read More » InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update November 14, 2024 Read More » InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules November 8, 2024 Read More » InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules November 5, 2024 Read More » InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease October 28, 2024 Read More » InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease October 24, 2024 Read More » InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board October 22, 2024 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update September 30, 2024 Read More » InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date September 20, 2024 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules June 27, 2025 Read More »
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 25, 2025 Read More »
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study June 24, 2025 Read More »
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA June 13, 2025 Read More »
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update May 12, 2025 Read More »
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update February 12, 2025 Read More »
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration February 3, 2025 Read More »
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study January 21, 2025 Read More »
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System November 19, 2024 Read More »
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update November 14, 2024 Read More »
InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules November 5, 2024 Read More »
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease October 28, 2024 Read More »
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease October 24, 2024 Read More »
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board October 22, 2024 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update September 30, 2024 Read More »
InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date September 20, 2024 Read More »
